Search

The article discusses a study to determine the possible role of partner and localizer of BRCA2 (PALB2) in sporadic hematological malignancies and its application for targeted therapeutic intervention. Topics discussed include PALB2 sequence changes, defects in the DNA damage response, lymphoblastoid cell lines, and protein truncation.

Focusing on disarmament, demobilization, and reintegration programs, this article considers why some armed groups disarm and demobilize, while others refuse to do so. Previous research focused on intergroup rivalries and identified enforcement as a critical barrier. This study considers the effect of (1) war benefits and (2) intragroup dynamics and argues that distribution problems obstruct conflict resolution. Using a simple game-theoretic model, the article demonstrates that optimal programs (1) consider that combatants' cost of supporting peace varies and (2) require a mix of positive and negative incentives to motivate all ex-combatants to participate and comply with program requirements. [ABSTRACT FROM AUTHOR]

ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional loss and chemoresistance. The introduction of new therapies, such as intensive chemoimmunotherapy and inhibition of B-cell receptor (BCR) signaling, has changed clinical responses for the majority of CLL tumors including those with 11q deletion, but it remains to be determined whether these strategies can prevent clonal evolution of tumors with biallelic ATM alterations. In this review we discuss ATM function and the consequences of its loss during CLL pathogenesis, differences in clinical behavior of tumors with monoallelic and biallelic ATM alterations, and we outline possible approaches for targeting the ATM null CLL phenotype. [ABSTRACT FROM AUTHOR]

The ATM-p53 DNA damage response pathway plays a crucial role in chemoresistance in chronic lymphocytic leukemia, as indicated by the adverse prognostic impact of deletions of 17p (locus of TP53) and 11q (locus of ATM) detected by fluorescence in situ hybridization (FISH) analysis. In addition to deletions, mutations in these respective genes are also associated with chemoresistance, and add to the prognostic information provided by FISH. In order to explore the possibility that dysfunction of the ATM-p53 pathway might also result from mechanisms other than ATM/ TP53 deletion/mutation, assays have been developed that probe the functional integrity of the ATM-p53 pathway. Currently, four different p53 function assays have been developed that are based on the measurement of p53 and p53-dependent genes at the RNA (real-time polymerase chain reaction [RT-PCR] p21; RT-PCR miR34a; reverse transcription-multiplex ligation-dependent probe amplification assay [RT-MLPA] p21, bax, puma and CD95) or protein (fluorescence activated cell sorting [FACS]p53-p21) level in untreated cells or following irradiation or drug treatment. Here we provide an overview of these assays based on the available literature. [ABSTRACT FROM AUTHOR]

Investigates the clonal diversity and T-cell receptor gene rearrangements in childhood B precursor acute lymphoblastic leukemia. Patterns of immune system gene rearrangements; Strategies to detect subclone formation; Biological role for clonal diversity; Mechanism for subclone formation among relapsing patients.